Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03065959 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03065959 is a Phase 1 study that was terminated before completion, run by Astellas Pharma Global Development. The registered enrollment target is 42 participants.
The verdict
NCT03065959, a Phase 1 study, was terminated before completion, sponsored by Astellas Pharma Global Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of CK-2127107 versus placebo on skeletal muscle fatigue assessed as change from baseline versus 14 days of treatment in sum of peak torque during isokinetic knee extensions. This study will also assess the effects of CK-2127107 on physical performance via a short physical performance battery (SPPB), stair-climb test and 6 minute walk test.
Interventions
- DRUG Placebo
- DRUG reldesemtiv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2018-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03065959
The ClinicalTrials.gov registry entry for NCT03065959 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03065959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03065959 about?
NCT03065959 is a clinical study titled "A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility". The purpose of this study is to investigate the effect of CK-2127107 versus placebo on skeletal muscle fatigue assessed as change from baseline versus 14 days of treatment in sum of peak torque during isokinetic knee extensions. This study will also assess the effects of CK-2127107 on physical perf...
What is the current status of trial NCT03065959?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-06-28. Estimated completion is 2018-10-10.
What interventions are being tested in trial NCT03065959?
The interventions under investigation include: Placebo (DRUG), reldesemtiv (DRUG).
Who is sponsoring clinical trial NCT03065959?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.